Canntab Therapeutics Limited announced that it has reached an agreement with 36Eight Technologies Inc — a bioinformatics pharmacological healthcare data and technology company — to help the cannabis company provide effective solutions for patients.
36Eight will list, market, and support all of Canntab's market-exclusive and patent-protected solid and exact dose cannabis products, the company shared.
"This is an exciting opportunity for Canntab, as we believe 36Eight's unique and valuable complementary platform will support our ability to provide effective solutions for patients while reinforcing the confidence of patients in their relationship with their clinical pharmacist," said Larry Latowsky, CEO of Canntab in a statement.
READ: Canntab Therapeutics brings in C$1,259,250 gross from early exercise of warrants
36Eight’s first-of-its-kind clinical artificial intelligence software and machine learning algorithm assist healthcare professionals in understanding drug-cannabis interactions, and better cater to a patient's unique medical needs.
"Canntab's product offerings are unlike any other product we support, as they are unique in that they provide exact dosage in a solid format, one that pharmacists and patients are comfortable with as a traditional delivery system," said John Tse, 36Eight's Founder and CEO. “We expect that with our software to support optimum care, our pharmacy partners will welcome and embrace Canntab's products."
Latowsky said that the partnership is the first of many affiliate programs with health and wellness practitioners including pharmacists, doctors, chiropractors, naturopaths, and sleep and pain clinics.
He added, “The number of Canadian Community Pharmacies alone is over 11,000. Programs like 36Eight and employing 36Eight's platform in conjunction with our own educational platforms will support and optimize the effective prescription dosage of medical cannabis products.”
The Toronto-based medical cannabis company focuses on manufacturing and distributing hard pill cannabinoid formulations in multiple doses and timed-release combinations for prescription and over-the-counter medications.
Contact Ritika at ritika@proactiveinvestors.com